Hims & Hers Health, Inc. (NYSE:HIMS) Receives $20.71 Average PT from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned an average recommendation of “Hold” from the sixteen analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.71.

HIMS has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th.

Hims & Hers Health Trading Down 1.1 %

Shares of HIMS stock opened at $30.35 on Thursday. The business’s 50-day moving average price is $21.14 and its 200-day moving average price is $19.57. Hims & Hers Health has a 12 month low of $8.09 and a 12 month high of $35.02. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. On average, sell-side analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the sale, the insider now owns 159,796 shares in the company, valued at $2,341,011.40. The trade was a 1.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now directly owns 145,763 shares in the company, valued at approximately $2,960,446.53. The trade was a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,153,519 shares of company stock worth $24,486,721 over the last quarter. 17.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HIMS. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the second quarter valued at approximately $111,000. Finally, Quarry LP boosted its position in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.